Article Text

Download PDFPDF

Effects of maternal medication on long-term outcome in congenital heart block remain to be established. Response to: ‘Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero’ by Satis et al
  1. Johannes Mofors1,
  2. Sven-Erik Sonesson2,
  3. Marie Wahren-Herlenius1
  1. 1 Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
  2. 2 Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hopsital, Stockholm, Sweden
  1. Correspondence to Marie Wahren-Herlenius, Department of Medicine, Karolinska Institutet, Stockholm 171 77, Sweden; marie.wahren{at}

Statistics from

We thank Satis and colleagues for opening the discussion on a potential influence of maternal immunomodulatory treatment on the long-term outcome of congenital heart block (CHB)1 and welcome their questions to help clarify some aspects of our study.2 Whether immunomodulatory treatment administered to the mother—as part of her own rheumatic disease treatment or intended to ameliorate the fetal cardiac inflammation in CHB—influences any outcome in CHB is a current matter of debate. Satis and colleagues cite several studies supporting a role …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles